Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …

We designed a randomized, placebo-controlled, multicentre trial involving 51 relapsing-remitting
multiple sclerosis patients to determine the clinical efficacy of mitoxantrone treatment …

The aim of this consensus paper was to define the state of the art on cognitive assessment of
persons with multiple sclerosis (PwMS), with the purpose of providing recommendations for …

Background Although several disease-modifying treatments are available for relapsing multiple
sclerosis, treatment effects have been more modest in progressive multiple sclerosis and …

Chorea is a movement disorder which may be associated with immunologic diseases, in
particular in the presence of antiphospholipid antibodies (aPL). Choreic movements have been …

Global grey matter (GM) loss has been reported in multiple sclerosis (MS). We addressed
the question of if and where GM loss is localized by means of optimized voxel-based …

We evaluated the effect of DMTs on Covid‐19 severity in patients with MS, with a pooled‐analysis
of two large cohorts from Italy and France. The association of baseline characteristics …

Objective During PREVENT (NCT01892345), eculizumab significantly reduced relapse risk
versus placebo in patients with aquaporin‐4 immunoglobulin G‐positive neuromyelitis …

Background The approval of 9-δ-tetrahydocannabinol and cannabidiol (THC:CBD)
oromucosal spray (Sativex) for the management of treatment-resistant multiple sclerosis (MS) …

Purpose To investigate the moderating role of resilience in the relationship between affective
disorders and Health-Related Quality of Life (HRQoL) for adolescents and young adults …